These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11333452)

  • 41. [Cytokines and anti-cytokine therapy in rheumatoid arthritis].
    Lorenz HM; Kalden JR
    Internist (Berl); 2001 Jan; 42(1):55-6, 59-63. PubMed ID: 11271621
    [No Abstract]   [Full Text] [Related]  

  • 42. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab.
    Hrycaj P; Korczowska I; Łacki JK
    Rheumatology (Oxford); 2003 May; 42(5):702-3. PubMed ID: 12709557
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B.
    Doubrawa E; Ricca RA; Malucelli TO; Pizzol VI; Barros DH; Paiva ES
    Rev Bras Reumatol; 2012 Aug; 52(4):653-5. PubMed ID: 22885430
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.
    Richette P; Dieudé P; Damiano J; Lioté F; Orcel P; Bardin T
    J Rheumatol; 2004 Oct; 31(10):2079-81. PubMed ID: 15468380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 46. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
    Danko JR; Gilliland WR; Miller RS; Decker CF
    Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Up-date on the use of infliximab in dermatology. Introduction].
    Sánchez-Carazo J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
    [No Abstract]   [Full Text] [Related]  

  • 48. [First scientific meeting of CRI (Rheumatism and Inflammation Club) under the patronage of FNSIM (French National Society of Internal Medicine) and FSR(French Society of Rheumatology) Paris, May 4, 2002].
    Grateau G; Geffray L; Veyssier-Belot C
    Rev Med Interne; 2002 Oct; 23(10):805-7. PubMed ID: 12428480
    [No Abstract]   [Full Text] [Related]  

  • 49. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 50. [Anti-TNF therapy in rheumatoid arthritis].
    Yakeuchi T; Amano K
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):7-15. PubMed ID: 15045810
    [No Abstract]   [Full Text] [Related]  

  • 51. [Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].
    Tomono K; Hashimoto S
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():573-8. PubMed ID: 15799420
    [No Abstract]   [Full Text] [Related]  

  • 52. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat.
    O'Dell JR
    Mayo Clin Proc; 2001 Jun; 76(6):573-5. PubMed ID: 11393494
    [No Abstract]   [Full Text] [Related]  

  • 53. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 54. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 55. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 56. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
    Hyrich KL; Silman AJ; Watson KD; Symmons DP
    Ann Rheum Dis; 2004 Dec; 63(12):1538-43. PubMed ID: 15242866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
    Goncalves DP; Laurindo I; Scheinberg MA
    J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
    [No Abstract]   [Full Text] [Related]  

  • 58. Extraarticular rheumatoid arthritis and drug-induced syndromes: understanding the role of tumor necrosis factor inhibitors.
    Bruyn GA
    J Rheumatol; 2004 Jul; 31(7):1461; author reply 1462. PubMed ID: 15229972
    [No Abstract]   [Full Text] [Related]  

  • 59. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
    Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974
    [No Abstract]   [Full Text] [Related]  

  • 60. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
    Kondo H
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.